Introduction

Huntington’s Disease (HD) is a devastating, autosomal dominant neurodegenerative disorder caused by a pathogenic CAG trinucleotide repeat expansion in the HTT gene on chromosome 4p16.3. This mutation results in an expanded polyglutamine tract in the huntingtin protein, leading to progressive neuronal dysfunction and cell death, primarily affecting the striatum and cortex. HD is characterized by a triad of motor, cognitive, and psychiatric symptoms, with a profound impact on patients’ quality of life and survival. This review provides an evidence-based, clinically focused overview of HD, emphasizing diagnostic criteria, pathophysiology, management, and emerging therapies.

Epidemiology

• Global Prevalence:
  HD affects 3–10 per 100,000 individuals in populations of European descent, with lower prevalence in Asian and African populations (Huntington’s Disease Society of America [HDSA], 2024).
  • Genetic Heterogeneity: The CAG repeat expansion is rare in non-European populations, necessitating culturally sensitive genetic counseling.
  • De Novo Mutations: Account for 1–3% of cases, often due to paternal germline instability (repeat expansion during spermatogenesis).
• U.S. Burden:
  Approximately 41,000 symptomatic individuals and 200,000 at-risk exist in the U.S., with a lifetime risk of ~1 in 10,000 for those with a family history (HDSA, 2024).

Genetic Transmission

• Inheritance Pattern:
  HD follows an autosomal dominant model. A single copy of the expanded HTT allele is sufficient to cause disease.
  • Penetrance:
    • ≥40 CAG repeats: Fully penetrant (100% risk of developing HD).
    • 36–39 repeats: Reduced penetrance (50–70% risk, with variable expressivity).
    • <35 repeats: Non-pathogenic.
  • Anticipation: Earlier onset in successive generations, particularly with paternal transmission due to male germline instability (e.g., 40+ repeats in fathers vs. 30–35 in mothers).

Clinical Presentation

Age of Onset

• Adult-Onset HD (most common):
  • 30–50 years (median age 40).
  • Progressive motor dysfunction, cognitive decline, and psychiatric symptoms.
• Juvenile Huntington’s Disease (JHD):
  • Onset <20 years (5–10% of cases).
  • Rapid progression with rigidity, bradykinesia, and seizures (30–50% of JHD cases).
  • Poor prognosis, often fatal within 10 years.

Core Symptom Clusters

1. Motor Symptoms:
   • Chorea: Initial hallmark (involuntary, jerky movements), often affecting face, limbs, and trunk.
   • Dystonia: Sustained muscle contractions (e.g., torticollis).
   • Bradykinesia/Rigidity: More prominent in juvenile HD; mimics Parkinson’s disease.
   • Gait Disturbance: Falls, instability, and progressive disability.
   • Dysarthria/Dysphagia: Speech impairment and aspiration risk.
   • Oculomotor Dysfunction: Saccadic eye movement abnormalities (e.g., “saccadic pursuit” deficits).
2. Cognitive Decline:
   • Executive Dysfunction: Early deficit in planning, decision-making, and working memory.
   • Memory Impairment: Progressive decline in episodic memory.
   • Processing Speed: Slowed information processing.
   • Subcortical Dementia: Advanced stages involve global cognitive deterioration.
3. Psychiatric/Behavioral Changes:
   • Depression: Often precedes motor symptoms; 50–70% of patients experience it.
   • Irritability, Apathy, Anxiety: Common in early stages.
   • Obsessive-Compulsive Behaviors: Repetitive rituals or thoughts.
   • Psychosis: Rare (5–10%), but may occur in advanced disease.

Juvenile Huntington’s Disease

• Atypical Presentation: Rigidity, tremor, and seizures dominate.
• Rapid Progression: High mortality due to complications like aspiration pneumonia or cardiac failure.

Diagnosis

Clinical Assessment

• Key Features: Progressive motor dysfunction, cognitive decline, psychiatric symptoms, and family history of HD.
• Differential Diagnosis: Rule out Wilson’s disease (Kayser-Fleischer rings), chorea-acanthocytosis, lupus, and other hereditary movement disorders.

Genetic Testing

• Gold Standard: HTT gene CAG repeat analysis via PCR or next-generation sequencing.
  • Interpretation:
    • ≥40 repeats: Fully penetrant.
    • 36–39: Reduced penetrance (50% risk of developing HD).
    • <35: Non-pathogenic.
  • Pre-symptomatic Testing: Indicated for at-risk individuals with informed consent and genetic counseling.

Neuroimaging

• MRI/CT:
  • Early Stages: Caudate nucleus atrophy (striatal volume loss).
  • Advanced Disease: Cortical thinning, ventricular enlargement, and white matter changes.
  • No Specific Biomarker: Imaging is supportive but not diagnostic.

Other Investigations

• Neuropsychological Testing: Assess executive function, memory, and processing speed.
• EEG: For seizure evaluation in JHD.

Management and Treatment

Symptom-Directed Therapies

1. Motor Symptoms:
   • Chorea:
     • Tetrabenazine/deutetrabenazine (VMAT2 inhibitors; FDA-approved).
     • Atypical Antipsychotics (e.g., olanzapine, risperidone) for chorea and psychiatric symptoms.
   • Parkinsonian Features: Levodopa may be trialed in juvenile HD.
   • Dystonia: Botulinum toxin injections or anticholinergics.
2. Psychiatric Symptoms:
   • Depression/Anxiety: SSRIs (e.g., sertraline) or SNRIs (e.g., venlafaxine).
   • Agitation/Aggression: Low-dose antipsychotics (e.g., risperidone, clozapine).
   • Psychosis: Antipsychotics with caution; consider clozapine for treatment-resistant cases.
3. Cognitive Decline:
   • No Disease-Modifying Therapies: Cognitive rehabilitation, caregiver education, and environmental modifications.

Supportive Care

• Speech/Language Therapy: Address dysarthria and dysphagia (e.g., modified diets, feeding tubes if needed).
• Nutritional Support: High-calorie diets; monitor for malnutrition.
• Physical Therapy: Improve gait stability, prevent falls, and maintain mobility.
• Occupational Therapy: Adaptive devices for ADLs (e.g., dressing, bathing).

Multidisciplinary Care

• Team Involvement: Neurologist, psychiatrist, genetic counselor, nutritionist, social worker, and palliative care specialist.

Prognosis and Mortality

• Life Expectancy: 15–20 years post-onset (varies by age and subtype).
• Common Causes of Death:
  • Aspiration Pneumonia (most frequent).
  • Falls/Trauma (e.g., hip fractures).
  • Nutritional Complications (e.g., cachexia).
  • Suicide: 5–10% of patients, often in early stages (high need for mental health monitoring).

Emerging Therapies and Research (2024)

• Huntingtin-Lowering Therapies:
  • Antisense Oligonucleotides (ASOs): Tominersen (targeting mutant HTT mRNA) shows target engagement in phase III trials but no significant clinical benefit yet.
  • RNAi Therapies: In preclinical stages, aiming to silence HTT expression.
• Gene Silencing: RNAi-based approaches (e.g., RG6042) are under investigation.
• Stem Cell and CRISPR Technologies: Preclinical studies explore neuronal replacement or gene editing, but clinical translation remains distant.
• Challenges: No therapy has yet halted progression; focus remains on symptom management and biomarker development (e.g., CSF HTT levels, neuroimaging).

Conclusion

HD is a complex, progressive disorder requiring early genetic diagnosis, multidisciplinary care, and patient-centered management. While no disease-modifying therapies are available, advances in huntingtin-lowering agents and gene silencing offer hope for future interventions. Clinicians must prioritize early diagnosis, psychological support, and advance care planning to optimize outcomes. Ongoing research underscores the urgency of translating molecular insights into clinical practice.

Key Resources

• Huntington’s Disease Society of America (HDSA): https://hdsa.org
• ClinicalTrials.gov: Search “Huntington’s disease” for ongoing trials.
• Guidelines: NICE (UK), AAN (U.S.), and EAN (European) recommendations for HD management.

This structured approach ensures clinicians can navigate the complexities of HD with evidence-based precision, while advocating for patients and families through education and support.